Alzheimer's Disease is a neurodegenerative disease where the build-up of the proteins amyloid and tau damage the nerve cells in the brain. A progressive disorder, Alzheimer’s develops over time with symptoms increasing in severity.
Between 60–80% of dementia cases are caused by Alzheimer's disease. Rapid diagnosis is important, as treatment early in the course of AD helps maintain cognitive and functional performance and delay the emergence of distressing behavioural and psychological symptoms, such as depression, anxiety and apathy.
Cholinesterase inhibitors can be used alone or in combination to manage the behavioural and psychological symptoms of Alzheimer's disease. However current treatments do not cure Alzheimer's disease and functional and cognitive decline are inevitable.
To find out more about Alzheimer's Disease visit our dedicated Learning Zone, which contains expert-led information on diagnosing behavioural and psychological symptoms, and the treatment options available.
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
<strong>Objectives: </strong>To define a practice guideline for biological treatment of dementia and to make transparent the development of the guideline connecting the original data with the resulting recommendations.
Related news and insights
AC Immune SA announced that Genentech, a member of the Roche Group, has informed the Company of top line results from a Phase II trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer’s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo.